Attana receives a Cell™ 250 instrument order from a European Life Science company
Attana has received an order for a Cell™ 250 instrument from a European Life Science company. This is the client’s second Attana instrument and is the result of a successful use and the client’s growth plans.The Cell™ 250 instrument will be installed during Q1 2022 and will positively affect Attana earnings in Q1 2022 and cash flow for the remainder of the year. “We strive to be close partner with our clients. This order is a result of this and our ability to grow together with our clients. We see good potential in increased further collaboration” comments Teodor Aastrup, CEO Attana.